NVR vs STRO · P/E 15, rev $10.52B vs rev $62.0M
NVR Inc (NVR) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
NVR Inc (NVR) is a residential construction company listed on NYSE.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported NVR revenue for 2024-12-31 was $10.52B. Net income was $1.68B. Revenue was up 10.6% from 2023-12-31 to 2024-12-31. NVR currently screens at market cap $16.94B and trailing P/E 15.3.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
NVR currently screens at market cap $16.94B and trailing P/E 15.3. STRO currently screens at market cap $470.8M.
Not investment advice. Open the NVR and STRO stock pages for the full models.
Not investment advice.